The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models
Clémenson, Céline, Jouannot, Erwan, Merino-Trigo, Ana, Rubin-Carrez, Chantal, Deutsch, Eric
Published in Investigational new drugs (01.04.2013)
Published in Investigational new drugs (01.04.2013)
Get full text
Journal Article
An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome
Boissel, Nicolas, de Botton, Stéphane, Thomas, Xavier G., Rao, Ercole, Bonnevaux, Hélène, Rubin-Carrez, Chantal, Guerif, Stéphane, Beys, Eric, Gosselin, Alice, Bauchet, Anne-Laure, Novikov, Valery, Fernandes, Elma, Wiederschain, Dmitri, Palatinsky, Emanuel A., Hsu, Karl, Fraenkel, Paula Goodman
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article